Kay’s argument centers on the potential price tag—roughly $20 million per year, according to Spotrac—and the difficulty of balancing Branch’s deal with long-term commitments to Jahmyr Gibbs, Jack Campbell, and possibly Sam LaPorta. He contends that waiting to assess Branch’s impact after his Achilles recovery could lead to a more informed, favorable deal.
Branch’s 2023 Defensive Rookie of the Year voting performance and his 2024 Pro Bowl nod showcased his high ceiling, but last season featured injuries and a suspension that tempered his momentum. The next question for Detroit is whether Branch returns fully healthy and at or near his 2024 level, which would influence both market value and negotiation leverage.
Achilles injuries complicate the evaluation. While many players rebound strongly, the risk of diminished explosiveness or speed after such an injury creates uncertainty about Branch’s long-term performance and, consequently, the optimal contract structure and duration.
Given the financial trade-offs, the analysis suggests Detroit could benefit from a cautious approach: extend other needs first, monitor Branch’s health and on-field return in 2026, and revisit a potential extension only after a clearer assessment of his post-injury impact.
Overall, the consensus is that delaying Branch’s extension may be prudent for the Lions, allowing them to preserve flexibility while evaluating his 2026 contribution and market value. Branch’s health and performance upon return will be the decisive factors in future negotiations.
